SCHEMBL20069495

SCHEMBL20069495

Cc1cccc(CC2(O)CCN(C(C)C)CC2)n1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PKLR P30613 1/20 0.43
OPRM1 P35372 4/20 0.40
OPRD1 P41143 4/20 0.40
OPRK1 P41145 4/20 0.40
OPRL1 P41146 4/20 0.40
HRH3 Q9Y5N1 3/20 0.39
GPR4 P46093 1/20 0.39
KCNH2 Q12809 1/20 0.39
CYP2D6 P10635 1/20 0.39
RET P07949 1/20 0.37
PARP1 P09874 1/20 0.35
KMT2A Q03164 2/20 0.33
PDE8B O95263 1/20 0.33
CDK2 P24941 1/20 0.32
CDK9 P50750 1/20 0.32
PRMT5 O14744 1/20 0.32
WDR77 Q9BQA1 1/20 0.32
MEN1 O00255 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12931208 0.84 PKLR (0.45) PKLROPRM1OPRD1OPRK1OPRL1
SCHEMBL20206044 0.83 PKLR (0.44) PKLROPRM1OPRD1OPRK1OPRL1
SCHEMBL16051125 0.81 PKLR (0.47) PKLROPRM1OPRD1OPRK1OPRL1
SCHEMBL20147400 0.79 CYP46A1 (0.50) PKLROPRM1OPRD1OPRK1OPRL1
SCHEMBL20147422 0.77 HRH3 (0.36) OPRM1OPRD1OPRK1OPRL1HRH3
SCHEMBL30273002 0.77 PKLR (0.39) PKLROPRM1OPRD1GPR4KCNH2
SCHEMBL16129840 0.77 PKLR (0.39) PKLROPRM1OPRD1GPR4KCNH2
SCHEMBL25499870 0.75 OPRM1 (0.40) OPRM1OPRD1OPRK1OPRL1HRH3
SCHEMBL29686152 0.74 GPR4 (0.49) PKLROPRD1OPRK1GPR4RET
SCHEMBL16049607 0.74 GPR4 (0.49) PKLROPRD1OPRK1GPR4RET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11648243-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2023-05-16 US disclosed
US-10441581-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2019-10-15 US disclosed
US-20180148445-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-31 US disclosed
US-20180133207-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed
US-20180134703-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed
US-20180133207-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed
WO-2018071454-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ANDREWS STEVEN W (US) 2018-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180148445-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 PKLR 1379/4885OPRM1 3497/4885OPRD1 2909/4885
US-11648243-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 PKLR 1379/4885OPRM1 3497/4885OPRD1 2909/4885
US-10441581-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 PKLR 1379/4885OPRM1 3497/4885OPRD1 2909/4885
US-20180133207-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 PKLR 1379/4885OPRM1 3497/4885OPRD1 2909/4885
US-20180134703-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 PKLR 1379/4885OPRM1 3497/4885OPRD1 2909/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.